Skip to main
MBOT

Microbot Medical (MBOT) Stock Forecast & Price Target

Microbot Medical (MBOT) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Microbot Medical is entering an exciting growth phase as they enter full market release (FMR) at the SIR annual scientific meeting this week, with a limited market release (LMR) that showed strong customer adoption and a shorter sales cycle compared to traditional surgical robots. With a targeted market of 2.5 million peripheral endovascular procedures in the US annually and an expanding sales footprint, we expect to see meaningful topline sales ramp-up during the remainder of 2026. With their innovative and unique fully disposable robotic system, proven successful in multiple procedures, and with Emory Healthcare's adoption, we anticipate favorable adoption by physicians and multi-billion-dollar revenues by FY29.

Bears say

Microbot Medical is positioning itself in the emerging market of robotic endoluminal surgery devices, but there are several fundamental risks to consider. These include slower-than-expected adoption, potential delays in securing international regulatory approvals, lack of profitability in the near term, and potential setbacks in expanding into neuro and cardio cases. Additionally, the lack of a dedicated reimbursement code for the company's LIBERTY system could present a barrier to adoption, despite the potential for attractive reimbursements for procedures enabled by the system.

Microbot Medical (MBOT) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Microbot Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Microbot Medical (MBOT) Forecast

Analysts have given Microbot Medical (MBOT) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Microbot Medical (MBOT) has a Strong Buy consensus rating as of May 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Microbot Medical (MBOT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.